

# Hyafilia

Dermal Filler

A Natural, Safe and Long-lasting Beauty Filler



# What is HyaFilia?

## ■ *Description*

- **HyaFilia** is used for **temporary improvement of wrinkles** by injecting it into the skin layer around the facial wrinkles.
- It is a **colorless and transparent gel-type product** with **viscoelasticity** composed of a **stabilized non-animal hyaluronic acid**.




## ■ *Indications*

- **HyaFilia** is tissue reconstructive material that intended to be used for **facial tissue augmentation**.
- It is recommended that the product be used for the correction of moderate to severe facial wrinkles, folds, and acne scars.


# Characteristics of HyaFilia




- **CE Mark approval (Feb 9, 2012)**
  - Class III
- **KFDA approval (May 16, 2012)**
  - Graft/prosthesis, biomaterial
  - B04230.01(4)



- **Through multicenter clinical trial, safety and efficacy of HyaFilia have been proven.**



- **Usage of HA produced by bacterial fermentation (*Streptococcus equi*)**
- **Biocompatibility**
  - Non-toxic
  - Non-immunogenic
- **Biodegradability**





- **BDDE cross-linked HA**
  - To overcome the short biodegradability of natural HA
  - Improvement of the sustainability
  - **Biphasic gel.**  
(Duration : 6-12 Month)

- **HA Conc.: 20 mg/ml (2%)**
- **High viscosity gel : 2,700,000 cP**
- **Injection Force: 10 N**



# Technology Used for HyaFilia



- ***BDDE cross-linked hyaluronic acid biphasic gel***

- The half-life of natural HA administered in the body is very short, so **it has to be modified in order to increase the stability *in vivo*.**


# Comparison between HA fillers

classification	HyaFilia	R-product	J-product
Composition	hyaluronic acid	hyaluronic acid	hyaluronic acid
Crosslinking agent	BDDE	BDDE	BDDE
Total HA concentration (mg/ml)	20	20	22~26
Complex viscosity(CP)	$2.7 \times 10^6$	$2.8 \times 10^6$	$0.9 \times 10^6$
Swelling ratio(ml/g)	4	2.8	3.8
Injection force(N)	10	9	13
Endotoxin(EU/ml)	Less than 0.25	Less than 0.5	-

- HyaFilia has similar chemical and physical features with R-product and J-product which are currently dominating the filler market. However, in the aspect of its swelling degree and enzyme stability, Hyafilia outweighs other products.

# Comparison between HA fillers

- Result of storage modulus( $G'$ ) measurement
  - HyaFilia had superior elasticity than R-product and J-product. Also, its cross-linking was proved to be stable as it showed steady  $G'$  value during the frequency variation.



➤ When filler's **storage modulus ( $G'$ )** is high...

- ✓ Elasticity is excellent
- ✓ Supporting power and duration is **outstanding** as stability of facial muscle movement is high

# Animal Studies: Safety

## ▪ Safety


- The following **biocompatibility and toxicology tests** were conducted on HyaFilia.

No	Test Title	Test Number	Test Standards	Test Results
1	Acute Systemic Toxicity Test	SNUH 0800401	ISO 10993-11	Pass
2	Subchronic Subcutaneous Toxicity and Implantation Test in Rat - 13 Weeks	SNUH 0800402	ISO 10993-11, ISO 10993-6	Pass
3	Cytotoxicity Test	SNUH 0800403	ISO 10993-5	Pass
4	The Guinea Pig Maximization Test	SNUH 0800404	ISO 10993-10	Pass
5	Hemolysis Test	SNUH 0800405	ISO 10993-4	Pass
6	Intracutaneous Reactivity Test	SNUH 0800406	ISO 10993-10	Pass
7	Pyrogen Test	SNUH 0800407	USP29	Pass
8	Bacterial Reverse Mutation Assay	SNUH 0800408	ISO 10993-3	Pass
9	In vitro Chromosome Aberration Test	SNUH 0800409	ISO 10993-3	Pass
10	In vivo Micronucleus Test	SNUH 0800410	ISO 10993-3	Pass
Testing Period		~ November 26 <sup>th</sup> 2009		
Testing Institution		Medical Device Evaluation Center, Clinical Research Institute, Seoul National University Hospital, Korea		

# Efficacy Test



- From the internal duration test using mouse, **Hyafil** had longer durability than J-product and similar durability with R-product.
- From the histological test, Hyafil showed superior result within the material remaining for 4months and connective tissues.

Plastic surgery division of Korea University Medical college (April, 2010)



16 weeks after injection

Internal Duration Test Result





# Clinical Data

## ■ Purpose of Clinical Trial

- In order to prove **non-inferiority** of **HyaFilia** compared to **R-product** in the aspect of **Nasolabial fold correction efficacy and safety**.

## ■ Clinical Trial Institution

Subject Number	CHA University Bundang CHA Hospital	Korea University Guro Hospital	Catholic University Seoul St. Mary's Hospital
68	20	30	18





# Clinical Data

## ■ Efficacy Evaluation

- Primary Efficacy Evaluation : **Prove Hyafilia is non-inferior** compared to R-product

- ✓ WSRS average difference between R-product applied area and Hyafilia applied area was  $-0.03 \pm 0.75$  .  
The lowest value of single one-sided 97.5% confidence interval regarding WSRS result was -0.22. As this was bigger value than -0.29 which was the non-inferiority limit in this trial, Hyafilia's non-inferiority was proved.




[독립적 평가자에 의해 평가된 WSRS 평균값 (FAS)]

# Clinical Data


## ■ Efficacy Evaluation

### • Secondary Efficacy Evaluation

- ✓ Patient's Satisfaction Level : Among GAI average value evaluated by subject on the 8<sup>th</sup> , 16<sup>th</sup>, and 24<sup>th</sup> week, Hyafilia's satisfaction level was higher than R-product on the 8<sup>th</sup> and 24<sup>th</sup> week. However, it is not statistically meaningful.



[Global Aesthetic Improvement (GAI)]



[각 시점에 피험자에 의해 평가된 GAI 평균값 (FAS)]

## ■ Conclusion

- **Hyafilia** used to improve nasolabial fold is considered as an **effective and safe** medical device.